Teachers Retirement System of The State of Kentucky Sells 880 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Teachers Retirement System of The State of Kentucky lessened its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 2.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 30,400 shares of the company’s stock after selling 880 shares during the period. Teachers Retirement System of The State of Kentucky’s holdings in Neurocrine Biosciences were worth $3,503,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Ashton Thomas Private Wealth LLC purchased a new position in Neurocrine Biosciences in the 2nd quarter worth approximately $28,000. Innealta Capital LLC purchased a new position in shares of Neurocrine Biosciences in the second quarter worth $30,000. EdgeRock Capital LLC bought a new position in shares of Neurocrine Biosciences during the second quarter valued at $35,000. Blue Trust Inc. boosted its position in shares of Neurocrine Biosciences by 171.9% during the third quarter. Blue Trust Inc. now owns 348 shares of the company’s stock valued at $40,000 after buying an additional 220 shares during the last quarter. Finally, Plato Investment Management Ltd increased its holdings in Neurocrine Biosciences by 44.1% in the 2nd quarter. Plato Investment Management Ltd now owns 425 shares of the company’s stock worth $59,000 after buying an additional 130 shares in the last quarter. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have issued reports on NBIX shares. Needham & Company LLC restated a “hold” rating on shares of Neurocrine Biosciences in a research note on Monday, November 11th. BMO Capital Markets decreased their target price on shares of Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating for the company in a research note on Thursday, October 17th. Raymond James restated an “outperform” rating and issued a $155.00 price target on shares of Neurocrine Biosciences in a research note on Thursday, October 10th. Piper Sandler upgraded Neurocrine Biosciences from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $131.00 to $159.00 in a research report on Thursday, August 29th. Finally, Barclays lowered their target price on Neurocrine Biosciences from $180.00 to $160.00 and set an “overweight” rating on the stock in a report on Monday, September 9th. Five research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $165.18.

Insiders Place Their Bets

In related news, insider Jude Onyia sold 2,331 shares of the stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $126.29, for a total transaction of $294,381.99. Following the completion of the transaction, the insider now directly owns 15,449 shares of the company’s stock, valued at approximately $1,951,054.21. This represents a 13.11 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 4.30% of the stock is currently owned by corporate insiders.

Neurocrine Biosciences Stock Down 0.1 %

NASDAQ NBIX opened at $126.70 on Friday. The business has a 50-day moving average price of $121.75 and a 200-day moving average price of $130.62. The firm has a market cap of $12.83 billion, a price-to-earnings ratio of 33.97 and a beta of 0.34. Neurocrine Biosciences, Inc. has a twelve month low of $110.95 and a twelve month high of $157.98.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.